title: Natalizumab and fingolimod: insight into their relative efficacies in clinical practice.
authors.affiliation: Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, USA.
authors.forename: Devon S
authors.initials: DS
authors.lastname: Conway
authors.affiliation: Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, USA cohenj@ccf.org.
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Cohen
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000914:Antibodies, Viral / Q000097:blood*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007577:JC Virus / Q000276:immunology*; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D011409:Propylene Glycols / Q000627:therapeutic use*; D012698:Serologic Tests; D013110:Sphingosine / Q000031:analogs & derivatives*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000914:Antibodies, Viral; D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D013110:Sphingosine